Clinical and morphological characteristic of the case of secondary enucleation of the eye with retinoblastoma
N. F. Bobrova, T. A. Sorochynska, O. V. Artiomov, M. V. Bryn.
SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
Purpose: To analyze case of secondary enucleation of a child’s eye with recurrent retinoblastoma (RB) developing due to parents’ failure to take the child to surveillance appointments after salvage eye therapy.
Material and Methods: Observation and treatment of a 10-month child diagnosed with bilateral RB. The right eye was diagnosed with RB at stage T1N0M0, and the left eye, with RB at stage T3cN0M0 complicated by secondary glaucoma.
Results: Salvage eye therapy was performed which included six cycles of combined multiagent chemotherapy (with systemic intravitreal chemoreduction melphalan injection), followed by three courses of laser coagulation of tumor focus in the right eye and additional seventh local chemotherapy in the left eye. As a result, type 4 RB regression pattern in the right eye, and was developed incomplete type 2 RB regression pattern (“fish-flesh” appearance) in the left eye. However, after the child did not visit the medical care facility for surveillance and treatment during seven months, tumor regrowth developed. Secondary enucleation of the left eye was performed due to big tumor size, anterior chamber involvement blindness, and the absence of visual functions without prospects for their improvement. Histopathology found undifferentiated retinoblastoma with invasion into the episclera, the child was administered two cycles of chemoreduction as well as external beam radiotherapy of the left orbit using a medical linear accelerator system.
Conclusion: Should tumor recurrence occur or if there is no tumor control, urgent secondary enucleation with eye ball histopathology and, if indicated, further adjuvant therapy are recommended to prevent metastasis and save child’s life.
1.Bobrova NF, editor. Retinoblastoma. Odessa: Izdatelskii tsentr; 2020. Russian.
2.Ianchenko TV. [Clinical and epidemiological risks for retinoblastoma in Kemerovo region] [Abstract of thesis for the degree of Cand Sc (Med)]. Moscow; 2015. Russian.
3.Abramson DH, Daniels AB, Marr BP, et al. Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Reti-noblastoma. PLoS One. 2016 Jan 12;11(1):e0146582. doi: 10.1371/journal.pone.0146582.
4.Bobrova NF, Sorochynska TA. [Method of combined treatment for retinoblastoma]. Patent of Ukraine UA 55690U. issued on December 27, 2018. Ukrainian.
5.Bobrova NF, Vit VV, Sorochynska TA, Smaglii DV. [Method of the eye globe enucleation in retinoblastomas with a high risk of optic nerve invasion]. Patent of Ukraine UA 124022. Bulletin No.5/2018 issued on March 12, 2018. Ukrainian.
6.Shields CL, Fulco EM, Arias JD, et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemo-therapy. Eye (Lond). 2013 Feb; 27(2): 253–64. doi: 10.1038/eye.2012.175.
7.Murphree AL, Villablanca JG, Deegan WF 3rd, et al. Chemotherapy plus local treatment in the management of intraocular reti-noblastoma. Arch Ophthalmol. 1996 Nov;114(11):1348-56. doi: 10.1001/archopht.1996.01100140548005.
8.Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Oph-thalmol. 1996 Nov;114(11):1330-8. doi: 10.1001/archopht.1996.01100140530002.
9.Francis JH, Roosipu N, Levin AM, et al. Current Treatment of Bilateral Retinoblastoma: The Impact of Intraarterial and Intravitre-ous Chemotherapy. Neoplasia. 2018 Aug; 20(8): 757–763.. doi: 10.1016/j.neo.2018.05.007.
10.Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004 Apr;9(2):69-73. doi: 10.1007/s10147-004-0392-6.
11.Carcaboso A.M., Chiappetta D.A., Opezzo J.A. Episcleral implants for topotecan delivery to the posterior segment of the eye. In-vest Ophthalmol Vis Sci. 2010 Apr;51(4):2126-34. doi: 10.1167/iovs.09-4050.
12.Mallipatna AC, Dimaras H, Chan HS. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol. 2011 Jun;129(6):738-45. doi: 10.1001/archophthalmol.2011.130.
13.Kaneko A, Suzuki S. Eye-Preservation Treatment of Retinoblastoma with Vitreous Seeding. Jap J Clin Oncol. 2003 Dec;33(12):601-7.
14.Munier FL, Gaillard MC, Soliman S, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibi-tion to conditional indications. Br J Ophthalmol. 2012 Aug;96(8):1078-83. doi: 10.1136/bjophthalmol-2011-301450.
15.Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015 Jun;122(6):1173-9. doi: 10.1016/j.ophtha.2015.01.017.
16.Bartuma K, Pal N, Kosek S, et al. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma. Acta Oph-thalmol. 2014 Aug;92(5):404-11. doi: 10.1111/aos.12282.
17.Ghose S, Nizamuddin SHM, Sethi A. Efficacy of induction chemotherapy in retinoblastoma, alone or combined with other adjuvant modalities. J Pediatr Ophthalmol. May-Jun 2002;39(3):143-50.
18.Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol. 2004. 2004;102:35-44; discussion 44-5.
19.Berry JL, Kogachi K, Murphree L, Jubran R, Kim JW. A Review of Recurrent Retinoblastoma: Children’s Hospital Los Angeles Classification and Treatment Guidelines. Int Ophthalmol Clin. Spring 2019;59(2):65-75. doi: 10.1097/IIO.0000000000000269.
20.Gündüz K, Günalp I, Yalçindağ N, et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors lead-ing to eventual treatment with external beam radiotherapy and enucleation. Ophthalmol. 2004 Oct;111(10):1917-24. doi: 10.1016/j.ophtha.2004.04.016.
21.Pavlidou E, Burris C, Thaung C, et al. Anterior Segment Seeding in Eyes With Retinoblastoma Failing to Respond to Intraophthal-mic Artery Chemotherapy. JAMA Ophthalmol. 2015 Dec;133(12):1455-8. doi: 10.1001/jamaophthalmol.2015.2861.
22.Fabian ID, Stacey A, Chowdhury T et al. High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes. Ophthalmology. 2017 Jun;124(6):851-858. doi: 10.1016/j.ophtha.2017.01.048.
23.Zhao J, Dimaras H, Massey C, et al. Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis. J Clin Oncol. 2011 Mar 1;29(7):845-51. doi: 10.1200/JCO.2010.32.5332.
24.Brennan RC, Qaddoumi I, Billups C, et al. Comparison of High-Risk Histopathologic Features in Eyes with Primary or Secondary Enucleation for Retinoblastoma. Br J Ophthalmol. 2015 Oct;99(10):1366-1371. doi: 10.1136/bjophthalmol-2014-306364.
25.Kopelman JE, McLean IW, Rosenberg SH. Multivariate analysis of risk factors for metastasis in retinoblastoma treated by enuclea-tion. Ophthalmology. 1987 Apr;94(4):371-7. doi: 10.1016/s0161-6420(87)33436-0.
26.Shields CL, Shields JA, Baew KA. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Br J Oph-thalmol. 1993 Sep;77(9):544-8. doi: 10.1136/bjo.77.9.544.
27.Eagle RC, Jr. High-Risk Features and Tumor Differentiation in Retinoblastoma. A Retrospective Histopathologic Study. Arch Pathol Lab Med. 2009 Aug;133(8):1203-9. doi: 10.5858/133.8.1203.
28.Kashyap S, Sethi S, Meel R, et al. A Histopathologic Analysis of Eyes Primarily Enucleated for Advanced Intraocular Retinoblas-toma from a Developing Country. Arch Pathol Lab Med. 2012 Feb;136(2):190-3. doi: 10.5858/arpa.2010-0759-OA.